Condition: Non-Muscle Invasive Bladder Neoplasms · Sponsor: Janssen Research & Development, LLC
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| Arkansas Urology | Little Rock, Arkansas, United States | Completed |
| Genesis Research LLC | Los Alamitos, California, United States | Active Not Recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Active Not Recruiting |
| University of California Irvine Medical Center | Orange, California, United States | Active Not Recruiting |
| Om Research LLC | San Diego, California, United States | Active Not Recruiting |
| Genesis Research LLC 1 | Sherman Oaks, California, United States | Completed |
| University of Colorado Cancer Center Anschultz Cancer Pavilion | Aurora, Colorado, United States | Completed |
| Colorado Clinical Research | Lakewood, Colorado, United States | Active Not Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Active Not Recruiting |
| Northwestern University | Chicago, Illinois, United States | Completed |
| First Urology | Jeffersonville, Indiana, United States | Completed |
| Wichita Urology Group | Wichita, Kansas, United States | Active Not Recruiting |
+ 181 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06319820